Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2

1. Danne, T.
2. Edelman, S.
3. Frias, J.P.
4. Ampudia-Blasco, F.J.
5. Banks, P.
6. Jiang, W.
7. Davies, M.J.
8. Sawhney, S.